Ansgar Heck
- Consultant, research coordinator; MD, PhD
Publications 2024
Acromegaly management in the Nordic countries: A Delphi consensus survey
Clin Endocrinol (Oxf), 101 (3), 263-273
DOI 10.1111/cen.15095, PubMed 38865284
Unravelling pituitary tumours in medically treated patients with acromegaly: the impact of systematic MRI reassessment
Acta Radiol, 65 (7), 753-758
DOI 10.1177/02841851241246107, PubMed 38659302
Precision medicine in Acromegaly: The Potential of Multimodal Therapy
J Clin Endocrinol Metab (in press)
DOI 10.1210/clinem/dgae636, PubMed 39288034
Long-term depot specific changes in adipose tissue after treatment of acromegaly
Eur J Endocrinol, 190 (3), K37-K42
DOI 10.1093/ejendo/lvae016, PubMed 38401530
No effect of surgery on kidney and cardiovascular risk factors in mild primary hyperparathyroidism: secondary analyses from a 10-year randomized controlled trial
Eur J Endocrinol, 191 (3), 354-360
DOI 10.1093/ejendo/lvae109, PubMed 39189547
Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors
Acta Neuropathol, 148 (1), 68
DOI 10.1007/s00401-024-02836-5, PubMed 39580368
Publications 2023
Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in acromegaly
Eur J Endocrinol, 188 (3)
DOI 10.1093/ejendo/lvad031, PubMed 36895180
Long-term control of acromegaly after pituitary surgery in South-Eastern Norway
Acta Neurochir (Wien), 165 (10), 3003-3010
DOI 10.1007/s00701-023-05772-7, PubMed 37665404
Endocortical Trabecularization in Acromegaly: The Cause for the Paradoxically Increased Vertebral Fracture Risk?
JBMR Plus, 7 (10), e10787
DOI 10.1002/jbm4.10787, PubMed 37808394
TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours
Pituitary, 26 (2), 227-236
DOI 10.1007/s11102-023-01310-x, PubMed 36952069
Positive Effect of Parathyroidectomy Compared to Observation on BMD in a Randomized Controlled Trial of Mild Primary Hyperparathyroidism
J Bone Miner Res, 38 (3), 372-380
DOI 10.1002/jbmr.4763, PubMed 36593641
Endoscopic four-hands technique for pituitary tumours
Tidsskr Nor Laegeforen, 143 (9)
DOI 10.4045/tidsskr.22.0693, PubMed 37341404
Publications 2022
European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders
Eur J Endocrinol, 186 (2), R33-R63
DOI 10.1530/EJE-21-1044, PubMed 34863037
Sex difference in patients with controlled acromegaly-A multicentre survey
Clin Endocrinol (Oxf), 98 (1), 74-81
DOI 10.1111/cen.14750, PubMed 35474467
Trends in incidence and mortality risk for acromegaly in Norway: a cohort study
Endocrine, 80 (1), 152-159
DOI 10.1007/s12020-022-03275-6, PubMed 36525222
Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation
Ann Intern Med, 175 (6), 812-819
DOI 10.7326/M21-4416, PubMed 35436153
Publications 2021
Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors
BMJ Case Rep, 14 (5)
DOI 10.1136/bcr-2021-241981, PubMed 34045201
The Influence of DXA Hardware, Software, Reference Population and Software Analysis Settings on the Bone Mineral Density and T-Score Relationship
J Clin Densitom, 25 (1), 24-33
DOI 10.1016/j.jocd.2021.07.002, PubMed 34393058
Publications 2020
Effects of Parathyroidectomy on Quality of Life: 10 Years of Data From a Prospective Randomized Controlled Trial on Primary Hyperparathyroidism (the SIPH-Study)
J Bone Miner Res, 36 (1), 3-11
DOI 10.1002/jbmr.4199, PubMed 33125769
Publications 2019
MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly
Eur J Endocrinol, 181 (2), R57-R71
DOI 10.1530/EJE-19-0124, PubMed 31100716
Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study
JBMR Plus, 3 (12), e10240
DOI 10.1002/jbm4.10240, PubMed 31844828
Publications 2018
Parathyroid hormone independent hypercalcemia in adults
Best Pract Res Clin Endocrinol Metab, 32 (5), 621-638
DOI 10.1016/j.beem.2018.06.005, PubMed 30449545
The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism
Endocr Connect, 7 (8), 941-948
DOI 10.1530/EC-18-0259, PubMed 30300532
Publications 2017
Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study
Eur J Endocrinol, 178 (1), 65-74
DOI 10.1530/EJE-17-0546, PubMed 28993415
Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study)
J Bone Miner Res, 32 (9), 1907-1914
DOI 10.1002/jbmr.3177, PubMed 28543873
Publications 2016
Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study
Eur J Endocrinol, 175 (2), 155-64
DOI 10.1530/EJE-16-0340, PubMed 27220351
[Not Available]
Tidsskr Nor Laegeforen, 136 (23-24), 2035
DOI 10.4045/tidsskr.16.0965, PubMed 28004565
Insulin sensitivity, body composition and adipose depots following 12 w combined endurance and strength training in dysglycemic and normoglycemic sedentary men
Arch Physiol Biochem, 122 (4), 167-179
DOI 10.1080/13813455.2016.1202985, PubMed 27477619
Publications 2015
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
Endocrine, 52 (2), 333-43
DOI 10.1007/s12020-015-0766-8, PubMed 26475495
MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly
Endocrine, 53 (1), 327-30
DOI 10.1007/s12020-015-0816-2, PubMed 26615593
Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas
Neuro Endocrinol Lett, 36 (2), 136-42
PubMed 26071582
Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism
J Clin Endocrinol Metab, 100 (4), 1359-67
DOI 10.1210/jc.2014-3441, PubMed 25636048
The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment
Neuroendocrinology, 103 (3-4), 197-206
DOI 10.1159/000371818, PubMed 25592241
Publications 2013
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide
J Clin Endocrinol Metab, 98 (11), E1730-9
DOI 10.1210/jc.2013-2145, PubMed 24092823
Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery
PLoS One, 8 (6), e66927
DOI 10.1371/journal.pone.0066927, PubMed 23825587
Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas
Endocrinology, 154 (9), 3331-43
DOI 10.1210/en.2013-1051, PubMed 23825128
Publications 2012
Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly
Clin Endocrinol (Oxf), 76 (1), 96-102
DOI 10.1111/j.1365-2265.2011.04163.x, PubMed 21722151
Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
Clin Endocrinol (Oxf), 77 (1), 72-8
DOI 10.1111/j.1365-2265.2011.04286.x, PubMed 22066905
Publications 2007
[Large goiter--diagnosis and treatment]
Tidsskr Nor Laegeforen, 127 (9), 1196-200
PubMed 17479138